Zura Bio (NASDAQ:ZURA) Shares Down 1.5% – What’s Next?

Zura Bio Limited (NASDAQ:ZURA) shares were down 1.5% during mid-day trading on Wednesday . The company traded as low as $5.07 and last traded at $5.24. Approximately 526,269 shares were traded during mid-day trading, a decline of 0% from the average daily volume of 526,941 shares. The stock had previously closed at $5.32.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ZURA. Wall Street Zen lowered shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research report on Tuesday, October 14th. Chardan Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a research note on Friday, November 14th. Finally, Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zura Bio has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Price Performance

The firm has a market capitalization of $340.70 million, a P/E ratio of -8.06 and a beta of 0.20. The company’s 50 day moving average price is $4.04 and its 200 day moving average price is $2.76.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). On average, research analysts anticipate that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

Several hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its holdings in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the last quarter. Scientech Research LLC acquired a new stake in shares of Zura Bio during the 3rd quarter worth approximately $45,000. Savant Capital LLC grew its position in shares of Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after buying an additional 21,249 shares during the period. Forefront Wealth Partners LLC bought a new stake in shares of Zura Bio during the third quarter worth approximately $93,000. Finally, Armistice Capital LLC lifted its holdings in Zura Bio by 1.6% in the third quarter. Armistice Capital LLC now owns 1,560,000 shares of the company’s stock valued at $6,755,000 after buying an additional 24,000 shares during the period. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.